Cutaneous Squamous Cell Carcinoma

• EMA approval · 2026-01-20
  EMA Authorised: Libtayo (cemiplimab) — Regeneron Ireland Designated Activity Company (DAC)

  The European Medicines Agency authorised Libtayo (cemiplimab) for the treatment of cutaneous squamous cell carcinoma (CSCC). Regeneron Irela…

• FDA approval · 2024-12-13
  FDA Approved: UNLOXCYT — Original Application (Sun Pharmaceutical Industries, Inc.)

  FDA approves UNLOXCYT (cosibelimab) in an original application from Sun Pharmaceutical for metastatic cutaneous squamous cell carcinoma.

• FDA approval · 2018-09-28
  FDA Approved: LIBTAYO — Original Application (Regeneron Pharmaceuticals, Inc.)

  The FDA granted original approval for LIBTAYO (cemiplimab-rwlc) from Regeneron Pharmaceuticals for cutaneous squamous cell carcinoma.